Clinical trials: Psychosis NOS
Psychosis, Dementia
A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
- Conditions
- Psychosis, Dementia, Aggression, Agitation
- Trial name
- NCT03044249
- Testing
- MP-101
- Where
- 20 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- Mediti Pharma Inc.
Schizophrenia, Schizoaffective Disorder
Cannabidiol Treatment in Patients With Early Psychosis
Cannabidiol (CBD) is a component of herbal cannabis that is present in varying concentrations in cannabis extracts. CBD has been shown to produce central effects including hypnotic, anticonvulsive, anxiolytic and neuroprotective…
- Trial name
- CBD (NCT02504151)
- Testing
- Cannabidiol
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Yale University
Psychosis
The Family Cognitive Adaptation Training Manual: A Test of Effectiveness
The purpose of this study is to examine the effectiveness of family cognitive adaptation training, including its impact on functioning and caregiver burden.
- Trial name
- NCT01768000
- Testing
- Family Cognitive Adaptation Training
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Centre for Addiction and Mental Health
Psychosis, Substance Abuse
Effect Evaluation of Individual Placement and Support (IPS)
Roughly one third of disability pensions issued in Norway are classified as mental and behavioral disorders. The proposed study aims to evaluate the effect of an innovative intervention for returning people with moderate to…
- Conditions
- Psychosis, Substance Abuse, Depression, Anxiety
- Trial name
- NCT01964092
- Testing
- Individual Placement and Support, Ordinary employment schemes
- Where
- Norway
- Volunteers
- 410 people
- Sponsor
- NORCE Norwegian Research Centre AS
Work-Related Condition
Survey of Correction Officers Before and After a Targeted Education Campaign
The investigators will implement a multifaceted Target Education Campaign (TEC) within the three jails about recognizing early psychotic symptoms and referring to the Correctional Health Services.
- Trial name
- COsurvey (NCT05451225)
- Testing
- Targeted Educational Campaign
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Columbia University
Psychosis
NAPLS Omega-3 Fatty Acid Versus Placebo Study
The overall goal of the present study is to determine whether Omega-3 Fatty Acids potentially prevent onset of psychosis and improve clinical symptoms and functional outcome in youth and young adults at elevated clinical risk for…
- Trial name
- NCT01429454
- Testing
- Omega-3 Long Chain Fatty Acid
- Where
- 9 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- University of California, San Diego
Schizophrenic Disorders
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and…
- Trial name
- NCT00660595
- Testing
- Quetiapine, Risperidone
- Where
- 4 sites in Finland
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Suicide, Psychosis
Cognitive Behavioral Suicide Prevention for Psychosis: Aim 1
The investigators are modifying and testing the preliminary effectiveness and implementation of a Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) intervention.
- Trial name
- NCT04689867
- Testing
- Cognitive Behavioral Suicide Prevention for psychosis CBSPp)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Parkinson's Disease Psychosis
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
- Trial name
- NCT01518309
- Testing
- pimavanserin tartrate (ACP-103)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Agitation
Treating Acutely Agitated Patients With Asenapine Sublingual Tablets
Our proposal is to administer asenapine to patients who are clinically agitated and in need of immediate intervention. At present there are no controlled studies that we know of that explores the use of asenapine for this…
- Trial name
- NCT01400113
- Testing
- Asenapine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Unity Health Toronto
Clinical High Risk for Psychosis
Glutamate Reducing Interventions in Schizophrenia
Participants will be administered several doses of pomaglumetad (POMA) (low and high doses) over 14 days to individuals at clinical high risk for developing psychosis and use magnetic resonance imaging (MRI) brain imaging to…
- Trial name
- NCT03321617
- Testing
- Pomaglumetad methionil
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia; Psychosis
Pharmacological Modulation of Hippocampal Activity in Psychosis 2
The purpose of this study is to test whether administration of levetiracetam (LEV), a commonly used anti-epileptic that alters neurotransmitter release, can reduce hippocampal hyperactivity in people with psychotic disorders.
- Trial name
- NCT04559529
- Testing
- Levetiracetam (LEV) 500 mg
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Schizophrenia
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
- Trial name
- NCT00254202
- Testing
- Iloperidone, Ziprasidone
- Where
- 42 sites in United States, India
- Volunteers
- 593 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
The primary aim of the study is to determine the efficacy of adjunctive valacyclovir, in comparison to placebo, to improve visual (Brief Visuospatial Memory Test) and working (composite score of the Spatial Span and Letter Number…
- Trial name
- VISTA (NCT02008773)
- Testing
- Valacyclovir HCI 500 mg tablets
- Where
- 13 sites in United States
- Volunteers
- 170 people
- Sponsor
- Indiana University
Psychosis Prodrome
Ziprasidone in the Psychosis Prodrome
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
- Trial name
- ZIP (NCT00635700)
- Testing
- ziprasidone
- Where
- 11 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Yale University
Schizophrenia, Schizophrenia; Psychosis
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
This is a Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter inpatient study to examine the efficacy and safety of KarXT in adult subjects who are acutely psychotic with a Diagnostic and…
- Trial name
- NCT04659161
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 22 sites in United States
- Volunteers
- 252 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Psychosis, Substance Use
Families With Substance Use and Psychosis: A Pilot Study
The purpose of this study is to develop and evaluate an intervention that adapts Community Reinforcement and Family Training (CRAFT) for families experiencing first episode psychosis and substance use delivered via telemedicine…
- Conditions
- Psychosis, Substance Use, Substance Use Disorders, Family
- Trial name
- NCT04284813
- Testing
- CRAFT-FT
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Psychosis
Social Cognition Intervention
Veterans with schizophrenia and schizoaffective disorder experience high levels of disability and poor community outcome, and these poor functional outcomes constitute a major public health concern.
- Trial name
- ASCI (NCT01267019)
- Testing
- social cognitive training with in vivo augmentation, social cognitive training, non-social skills training
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- VA Office of Research and Development
Childhood Schizophrenia, Psychotic Disorder
Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
The purpose of this study is to compare the effectiveness and side effects of the drugs clozapine and olanzapine in children and adolescents with schizophrenia and psychoses.
- Conditions
- Childhood Schizophrenia, Psychotic Disorder, Schizophrenia
- Trial name
- NCT00001656
- Testing
- Olanzapine, Clozapine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Mental Health (NIMH)
Parkinson's Disease, Psychotic Disorders
Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease
The purpose of this study is to evaluate the safety and efficacy of three target doses of melperone compared to placebo in the treatment of psychosis associated with Parkinson's disease.
- Trial name
- NCT00125138
- Testing
- Melperone HCl
- Where
- 21 sites in United States, India and 1 more
- Volunteers
- 90 people
- Sponsor
- Lundbeck LLC